Human papillomavirus vaccination in the prevention of cervical neoplasia.
Astbury, Katharine Turner, Michael J
Astbury, Katharine
Turner, Michael J
Authors
Advisors
Editors
Other Contributors
Date
2012-02-01T10:58:21Z
Date Submitted
Keywords
Other Subjects
Subject Mesh
Cervical Intraepithelial Neoplasia/etiology/immunology/*prevention & control
Female
Humans
Immunity, Active/physiology
Male
Papillomavirus Infections/complications/immunology/*prevention & control
Papillomavirus Vaccines/biosynthesis/immunology/*therapeutic use
Treatment Outcome
Uterine Cervical Neoplasms/etiology/immunology/*prevention & control
*Vaccination/economics/methods
Female
Humans
Immunity, Active/physiology
Male
Papillomavirus Infections/complications/immunology/*prevention & control
Papillomavirus Vaccines/biosynthesis/immunology/*therapeutic use
Treatment Outcome
Uterine Cervical Neoplasms/etiology/immunology/*prevention & control
*Vaccination/economics/methods
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Cervical cancer remains a major cause of morbidity and mortality for women worldwide. Although the introduction of comprehensive screening programs has reduced the disease incidence in developed countries, it remains a major problem in the developing world. The recent licensing of 2 vaccines against human papillomavirus (HPV) type 16 and HPV-18, the viruses responsible for 70% of cervical cancer cases, offers the hope of disease prevention. In this article, we review the role of HPV in the etiology of cervical cancer and the evidence to support the introduction of vaccination programs in young women and discuss the potential obstacles to widespread vaccination. In addition, we discuss the issues that remain to be elucidated, including the potential need for booster doses of the vaccine and the role of concomitant vaccination in men.
Language
eng
ISSN
1525-1438 (Electronic)
1048-891X (Linking)
1048-891X (Linking)
eISSN
ISBN
DOI
10.1111/IGC.0b013e3181a8411b
PMID
19955947